The global tildrakizumab market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Tildrakizumab is a monoclonal antibody used to treat inflammatory diseases caused by the lack of immunity. Various diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis can be treated with tildrakizumab (AS). One of the major factors driving the demand of the tildrakizumab drug is the rising prevalence of atopic illnesses such as psoriasis, ecthyma, and eczema, among others.
(Get 15% Discount on Buying this Report)
A full report is available at : https://orionmarketreports.com/global-tildrakizumab/92759/
Additionally, skin irritants occur due to the use of certain soaps, detergents, perfumes, and other skin & beauty products. Thus, allergic reactions is another major factor that are increasing the burden of atopic dermatitis and driving the growth of the tildrakizumab market. For instance, in May 2018, the US Food and Drug Administration (USFDA) approved Sun Pharmaceuticals’ biologics license application (BLA) for ILUMYA. Schering-Plough merged with Merck & Co, a US-based pharmaceutical company, and developed the medication. Merck & Co. sold Sun Pharmaceuticals’ the global rights to ILUMYA for $80 million. Adults with moderate-to-severe plaque psoriasis should use ILUMYA (tildrakizumab-asmn), a subcutaneous infusion.
Market Coverage
The market number available for – 2022-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
By Application
By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
Rest of the World
- Competitive Landscape–NCK Pharma Solution Ltd., Almirall, S.A, Sun Pharmaceutical Industries Ltd. among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How are playersaddressing challenges to sustain growth?
- Where is the investment opportunity?
Global Methylphenidate Drug Market Report by Segment
By Type
- Prefilled 100mg/mL solution
- Type II
By Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name : Orion Market Reports
Contact Person : Mr. Anurag Tiwari
Email : Info@orionmarketreports.com
Contact No : +91 780-304-0404
This release has been published on Global market Post
Global market Post is not responsible for any content included in this release.
